Furiex Pharmaceuticals, Inc. Puts Itself Up For Sale As Experimental Drug Meets Targets

Published: Feb 20, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Furiex Pharmaceuticals Inc. (FURX), the drug developer whose irritable bowel treatment is moving toward regulatory approval, is working with Bank of America Corp. to find a buyer, people with knowledge of the matter said. Now that the medicine has met targets developed in conjunction with U.S. and European regulators, management believes there is less risk for buyers and has begun contacting other drugmakers to gauge their interest in a deal, said two of the people, who asked not to be named because the Morrisville, North Carolina-based company’s plans are private. Furiex’s experimental treatment eluxadoline alleviated diarrhea and abdominal pain caused by irritible bowel syndrome in two studies, the last of three rounds generally needed for regulatory clearance.

Help employers find you! Check out all the jobs and post your resume.

Back to news